Skip to main content
University of California San Francisco
About UCSF
Search UCSF
UCSF Medical Center
Radiology
About
People
Opportunity and Outreach
Wellbeing and Professional Climate
Strategic Plan
Locations
Make a Gift
Contact Us
Patient Care
Clinical Divisions
For Patients
For Health Professionals
Services Offered
Education
Diagnostic Radiology Residency
Integrated IR Residency
Independent IR Residency
NucMed Residency & Fellowship
Fellowships
T32 Program
Medical Student Education
Master of Science in Biomedical Imaging (MSBI)
Continuing Medical Education
Ultrasound Lecture Series
The Margulis Society for Alumni
Distinguished Lecture Series
Research
Research Directory
Imaging Research Symposium
Research Conference
UCSF Radiology at RSNA
ISMRM
Core Services
Academic Affairs
Academic Recruitment
Academic Advancement
Development & Courses
Faculty Mentoring
Faculty Thrive Guide
Celebrating Faculty & Alumni
Department Committees
FAQs
News
Events
Honors and Awards
Department Publications
Search
Breadcrumb
Home
/
About
/
People
/
Laura Esserman, MD
/
Publications
Laura Esserman, MD, MBA's Publications
A prospective single-arm pilot study evaluating [F-18]fluoroestradiol dedicated breast PET in invasive lobular carcinoma after neoadjuvant endocrine therapy.
Author Correction: Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial.
Biological subphenotypes in severe acute hypoxaemic respiratory failure and acute respiratory distress syndrome using rapid prospective classification (SPARC) in the USA: a multicentre, observational, study.
Breast cancer risk level and prediction of tumor aggressiveness in the Athena Breast Health Network.
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.
Hormone signaling and immune programs define differential endocrine responsiveness in high-risk breast tissue.
Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.
Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting.
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer.
RISE UP for breast cancer 2024: conference highlights & takeaways.
Screening for Breast Cancer-Reply.
Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers.
WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design.
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.
Bilateral Mastectomy vs Lumpectomy and Breast Cancer Mortality Risk.
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
Correction: A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.
Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.
Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.
FNA biopsy of breast specimens effectively harvests cells for patient-derived organoids modeling ductal carcinoma in situ.
Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical Trial.
Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers.
Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer.
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
Impact of IVF Restriction on Patients With Cancer and Surgeons.
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.
Implantation of engineered adipocytes suppresses tumor progression in cancer models.
Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events.
Integrating breast cancer polygenic risk scores at scale in the WISDOM Study: a national randomized personalized screening trial.
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.
Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer.
National yearly cost of breast cancer screening in the USA and projected cost of advocated guidelines: a simulation study with life table modelling.
Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial.
Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapies.
Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancer.
Pilot Study: A Prospective Placebo-control Trial Evaluating Topical Tranexamic Acid in Postmastectomy Breast Reconstruction.
Pilot Study: Investigating the Local Breast Microbiome in Implant-based Breast Reconstruction Using 16S rRNA Sequencing.
Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial.
Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.
Socioeconomic status impacts tumor biology, treatment, and outcomes in over 200,000 patients with invasive lobular carcinoma of the breast: an analysis of the National Cancer Database.
Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial.
Translating risk-based breast cancer screening to limited-resource settings.
WISDOM Randomized Trial Comparing Risk-Based Versus Annual Breast Cancer Screening: Study Cohort Characteristics and Design.
18F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy.
A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.
Anti-CD14 treatment in patients with severe COVID-19: Clinical and biological effects in a Phase 2 randomized open-label adaptive platform clinical trial.
Balancing risks of surgical complications and positive margins for patients with invasive lobular carcinoma of the breast and elevated BMI: An institutional cohort study.
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer.
Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis.
Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial.
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Duration of Endocrine Treatment for DCIS impacts second events: Insights from a large cohort of cases at two academic medical centers.
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women.
Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody-Drug Conjugates (ADCs).
Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial.
Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for Evidence.
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial.
Overcoming challenges in conducting early phase breast cancer prevention trials: Bazedoxifene and conjugated estrogens vs waitlist control.
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Precision Oncology in Breast Cancer Surgery.
RE: Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density.
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
Relationship Between Perceived COVID-19 Risk and Change in Perceived Breast Cancer Risk: Prospective Observational Study.
Reproductive rights in the United States: acquiescence is not a strategy.
Screening Mammography for 40-Year-Old Women-Whose Decision?
Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers.
Tumor microenvironmental determinants of high-risk DCIS progression.
Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective Study.
Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study.
A Truly Pro-Life Position Requires Access to Reproductive Health Care.
Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes.
Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.
Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study.
Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
Concordance between patient-reported and physician-documented comorbidities and symptoms among Stage 4 breast cancer patients.
Development and testing of a polygenic risk score for breast cancer aggressiveness.
Early Ascertainment of Breast Cancer Diagnoses Comparing Self-Reported Questionnaires and Electronic Health Record Data Warehouse: The WISDOM Study.
Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
Expanding Candidacy for Nipple-sparing Mastectomy in Women with Large or Ptotic Breasts: Staged Reconstruction Outcomes.
Guiding principles for the responsible development of artificial intelligence tools for healthcare.
Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression.
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification.
Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy.
Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply.
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy.
The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database.
Time to Surgery in Breast Cancer-Is Faster Always Better?
Validation Study on Risk-Reduction Activities after Exposure to a Personalized Breast Cancer Risk-Assessment Education Tool in High-Risk Women in the WISDOM Study.
When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node.
Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply.
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy.
Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer.
Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship-Associated Distress: Survey Study.
Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment.
I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations.
Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
Informed consent process in the ISPY COVID trial is ethically acceptable.
Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting.
Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
Survivorship after neoadjuvant chemotherapy - Authors' reply.
The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ.
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study.
Why It Is Time to Challenge Entrenched Beliefs About Breast Cancer Screening.
A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer.
A world-wide survey on kidney transplantation practices in breast cancer survivors: The need for new management guidelines.
Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma.
Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast: Factors associated with false negatives.
Advancing precision medicine for acute respiratory distress syndrome.
Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
Authors' Reply: To the Letter to the Editor by Groheux et al.
Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.
Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence.
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability.
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry.
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
Health screening needs independent regular re-evaluation.
Incorporation of Patient-Reported Outcomes Measurement Information System to assess quality of life among patients with breast cancer initiating care at an academic center.
Mask-Guided Convolutional Neural Network for Breast Tumor Prognostic Outcome Prediction on 3D DCE-MR Images.
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies.
Pre-Appointment Nurse Navigation: Patient-Centered Findings From a Survey of Patients With Breast Cancer.
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial.
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.
The use of neoadjuvant therapy to further personalize breast cancer treatment.
The WISDOM study: a new approach to screening can and should be tested.
Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief.
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater.
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy.
Cost-effectiveness of consensus guideline based management of pancreatic cysts: The sensitivity and specificity required for guidelines to be cost-effective.
Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Evaluating the impact of axillary dissection on recurrence-free survival by extent of nodal disease in invasive lobular carcinoma of the breast.
Evaluation of primary breast cancers using dedicated breast PET and whole-body PET.
Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial.
Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial.
Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
Mutational profiling of micro-dissected pre-malignant lesions from archived specimens.
Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience.
Personalization of Treatment is the Way Forward in Care and Trials.
Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.
Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.
Prime Time for Consultation Audio Recordings: Supporting Shared Decision Making During and After the COVID-19 Era.
Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
Response to Carter et al.
The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment.
The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology.
Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer.
Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis.
We need more evidence to answer questions about screening.
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel.
A response to "Personalised medicine and population health: breast and ovarian cancer".
Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.
Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.
Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
Evaluation of National Comprehensive Cancer Network guideline-based Tool for Risk Assessment for breast and ovarian Cancer (N-TRAC): A patient-reported survey for genetic high-risk assessment for breast and ovarian cancers in women.
Fitbit Usage in Patients With Breast Cancer Undergoing Chemotherapy.
Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
Should we rename low risk cancers?
Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast.
Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches.
Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
Complications After Total Skin-Sparing Mastectomy and Expander-Implant Reconstruction: Effects of Radiation Therapy on the Stages of Reconstruction.
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis.
Functional Status and Survival After Breast Cancer Surgery in Nursing Home Residents.
Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer.
Improved analgesia and reduced post-operative nausea and vomiting after implementation of an enhanced recovery after surgery (ERAS) pathway for total mastectomy.
Initial Clinical Experience With an Inducible Magnetic Seed System for Preoperative Breast Lesion Localization.
Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
Precision risk-based screening might maximize benefit and minimize harm.
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers.
Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.
The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia.
Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.
Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.
Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.
Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.
Precision surgery and avoiding over-treatment.
Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels.
Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
The value of embedding: integrated palliative care for patients with metastatic breast cancer.
The WISDOM Study: breaking the deadlock in the breast cancer screening debate.
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
Adaptive Randomization of Neratinib in Early Breast Cancer.
Adaptive Randomization of Neratinib in Early Breast Cancer.
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
CLINICAL DECISIONS. Ductal Carcinoma In Situ.
Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.
Detection of ductal carcinoma in situ and subsequent interval cancers.
Do Prolonged Prophylactic Antibiotics Reduce the Incidence of Surgical-Site Infections in Immediate Prosthetic Breast Reconstruction?
Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.
Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.
Laura Esserman and Ian Thompson Discuss Strategies for Screening and Treatment of Early-Stage Cancers, and How Clinicians Can Learn From Each Other's Experiences.
Less Is More: The Evolving Surgical Approach to Breast Cancer.
MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial.
Neoadjuvant as Future for Drug Development in Breast Cancer--Response.
Outcomes Following Oncoplastic Reduction Mammoplasty: A Systematic Review.
PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.
Population-based screening for cancer: hope and hype.
Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers.
The I-SPY approach to drug development.
The Impact of Radiation Therapy, Lymph Node Dissection, and Hormonal Therapy on Outcomes of Tissue Expander-Implant Exchange in Prosthetic Breast Reconstruction.
The Novel Application of Genomic Profiling Assays to Shorten Inactive Status for Potential Kidney Transplant Recipients With Breast Cancer.
Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?
Tissue Expander Reconstruction After Total Skin-Sparing Mastectomy: Defining the Effects of Coverage Technique on Nipple/Areola Preservation.
Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ-Reply.
When Less Is Better, but Physicians Are Afraid Not to Intervene.
When the Gold Standard Loses Its Luster, Perhaps It Is Time to Change Nomenclature.
Approaches to microvascular breast reconstruction after total skin-sparing mastectomy: a comparison of techniques.
Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer.
Coaching patients in the use of decision and communication aids: RE-AIM evaluation of a patient support program.
Comparison of Mammographic Findings Following Oncoplastic Mammoplasty and Lumpectomy Without Reconstruction.
Development, implementation, and initial evaluation of a foundational open interoperability standard for oncology treatment planning and summarization.
Expanding the Indications for Total Skin-Sparing Mastectomy: Is It Safe for Patients with Locally Advanced Disease?
How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.
In Regard to Hepel and Wazer.
Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer.
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care.
Pride, Prejudice, or Science: Attitudes Towards the Results of the TARGIT-A Trial of Targeted Intraoperative Radiation Therapy for Breast Cancer.
Rates of Reconstruction Failure in Patients Undergoing Immediate Reconstruction With Tissue Expanders and/or Implants and Postmastectomy Radiation Therapy.
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
Rethinking the Standard for Ductal Carcinoma In Situ Treatment.
Sentinel Lymph Node Mapping in Post-Mastectomy Chest Wall Recurrences: Influence on Radiation Treatment Fields and Outcome.
Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
The impact of breast mass on outcomes of total skin-sparing mastectomy and immediate tissue expander-based breast reconstruction.
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
Tumor Involvement of the Nipple in Total Skin-Sparing Mastectomy: Strategies for Management.
Abstract 124: outcomes of total skin-sparing mastectomy and reconstruction in 924 breasts over 11 years.
Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change?
Addressing overdiagnosis and overtreatment in cancer: a prescription for change.
Aggregate cost of mammography screening in the United States.
Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines.
Application of a decision analytic framework for adoption of clinical trial results: are the data regarding TARGIT-A IORT ready for prime time?
Changing the terminology of cancer--reply.
Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease.
Development of a personalized decision aid for breast cancer risk reduction and management.
Expression profiling of circulating tumor cells in metastatic breast cancer.
Fifty years of age-based screening: time for a new risk-based screening approach.
Haste makes waste, but lack of urgency is opportunity lost.
Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis.
Immediate implant-based breast reconstruction following total skin-sparing mastectomy in women with a history of augmentation mammaplasty: assessing the safety profile.
Immediate implant-based breast reconstruction following total skin-sparing mastectomy: defining the risk of preoperative and postoperative radiation therapy for surgical outcomes.
Impact of total skin-sparing mastectomy incision type on reconstructive complications following radiation therapy.
Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).
Making better doctors: a survey of premedical interns working as health coaches.
Mammographic screening detects low-risk tumor biology breast cancers.
Moving beyond the breast cancer screening debate.
Oncoplastic mammoplasty as a strategy for reducing reconstructive complications associated with postmastectomy radiation therapy.
Patient-reported outcomes and satisfaction after total skin-sparing mastectomy and immediate expander-implant reconstruction.
Preoperative Breast Pain Predicts Persistent Breast Pain and Disability After Breast Cancer Surgery.
Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657).
Randomized trial of drain antisepsis after mastectomy and immediate prosthetic breast reconstruction.
Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform.
Setting a research agenda for ductal carcinoma in situ that meets the current need for change.
SIS.NET: a randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer.
Total skin-sparing mastectomy and immediate breast reconstruction: an evolution of technique and assessment of outcomes.
An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.
Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer.
Developing safety criteria for introducing new agents into neoadjuvant trials.
Evolving paradigm for imaging, diagnosis, and management of DCIS.
Feasibility of Performing Total Skin-Sparing Mastectomy in Patients With Prior Circumareolar Mastopexy or Reduction Mammoplasty Incisions.
Impact of ductal carcinoma in situ terminology on patient treatment preferences.
Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.
Overdiagnosis and overtreatment in cancer: an opportunity for improvement.
Patient preferences regarding intraoperative versus external beam radiotherapy following breast-conserving surgery.
Recognising the benefits and harms of breast cancer screening: an opportunity to target improvement.
Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention.
Reply: The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy.
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.
Screening: biology dictates the fate of young women with breast cancer.
The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and care.
The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
Total skin-sparing mastectomy in BRCA mutation carriers.
Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications.
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.
Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.
Adoption, acceptability, and accuracy of an online clinical trial matching website for breast cancer.
Biology of breast cancer in Nigerian women: a pilot study.
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.
Breast cancer recurrence is dictated by high-risk biology, not choice of surgery.
Breast cancer screening: the questions answered.
Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
Evaluating the feasibility of extended partial mastectomy and immediate reduction mammoplasty reconstruction as an alternative to mastectomy.
Increasing the time to expander-implant exchange after postmastectomy radiation therapy reduces expander-implant failure.
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts.
Overdiagnosis and overtreatment of breast cancer.
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
Physician behaviors surrounding the implementation of decision and communication AIDS in a breast cancer clinic: a qualitative analysis of staff intern perceptions.
Targeting Molecular Aberrations in Breast Cancer: Is It about Time?
The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study.
The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors.
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Will early detection for breast cancer ever work?
Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors.
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
Accelerating identification and regulatory approval of investigational cancer drugs.
Biologic markers determine both the risk and the timing of recurrence in breast cancer.
Characterizing the impact of 25 years of DCIS treatment.
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.
Impact of mammographic screening on the detection of good and poor prognosis breast cancers.
Leukocyte composition of human breast cancer.
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).
Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ.
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ.
Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.
Expanding the reach of decision and communication aids in a breast care center: a quality improvement study.
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.
Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction.
Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients: a meta-analysis and single-institution experience.
Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins?
Lessons learned from genetic testing.
Long-term prognostic role of functional limitations among women with breast cancer.
Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome.
Solving the overdiagnosis dilemma.
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.
The Communication and Care Plan: a novel approach to patient-centered clinical information systems.
A comparison of RNA amplification techniques at sub-nanogram input concentration.
Application of screening principles to the reconstructed breast.
Bacteriologic features of surgical site infections following breast surgery.
Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients.
I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis.
Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
Prognostic implications of positive nonsentinel lymph nodes removed during selective sentinel lymphadenectomy for breast cancer.
Rethinking screening for breast cancer and prostate cancer.
The UCSC Cancer Genomics Browser.
Total skin-sparing mastectomy: complications and local recurrence rates in 2 cohorts of patients.
Converting evidence to practice: a guide for the clinical application of MRI for the screening and management of breast cancer.
Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.
Is it necessary to harvest additional lymph nodes after resection of the most radioactive sentinel lymph node in breast cancer?
Monitoring the implementation of Consultation Planning, Recording, and Summarizing in a breast care center.
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.
Optimizing the total skin-sparing mastectomy.
Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates.
Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.
Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model.
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.
Training community resource center and clinic personnel to prompt patients in listing questions for doctors: follow-up interviews about barriers and facilitators to the implementation of consultation planning.
When informed, all women do not prefer breast conservation.
A role for biomarkers in the screening and diagnosis of breast cancer in younger women.
Analysis of molecular inversion probe performance for allele copy number determination.
Ductal carcinoma in situ in BRCA mutation carriers.
Fluorescence in situ hybridization of ductal lavage samples identifies malignant phenotypes from cytologically normal cells in women with breast cancer.
Pilot trial of a computerized decision aid for breast cancer prevention.
Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes.
Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ.
Breast cancer growth prevention by statins.
Breast cancer risk assessment and prevention: a framework for shared decision-making consultations.
Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
Clinical trials are required to prove the chemopreventive worth of statins.
Evaluation of a visit preparation intervention implemented in two rural, underserved counties of Northern California.
Genetic/familial high-risk assessment: breast and ovarian.
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
Magnetic resonance imaging captures the biology of ductal carcinoma in situ.
Mammographic, sonographic, and pathologic characteristics of Burkitt's lymphoma in a patient referred for diagnostic mammography.
Type and duration of exogenous hormone use affects breast cancer histology.
Development of a novel method for measuring in vivo breast epithelial cell proliferation in humans.
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
Immune dysfunction and micrometastases in women with breast cancer.
Integration of imaging in the management of breast cancer.
Internal mammary sentinel lymph node mapping for invasive breast cancer: implications for staging and treatment.
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
Primary tumor characteristics predict sentinel lymph node macrometastasis in breast cancer.
Ratio of positive to total number of sentinel nodes predicts nonsentinel node status in breast cancer patients.
Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital.
Safety of immediate transverse rectus abdominis myocutaneous breast reconstruction for patients with locally advanced disease.
Statins: health-promoting agents show promise for breast cancer prevention.
Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis.
The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer.
Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation.
Applying the neoadjuvant paradigm to ductal carcinoma in situ.
Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma.
Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis.
Neoadjuvant chemotherapy for primary breast cancer: lessons learned and opportunities to optimize therapy.
Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results.
An XML message broker framework for exchange and integration of microarray data.
Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium.
Efficacy of computerized infrared imaging analysis to evaluate mammographically suspicious lesions.
Failure to harvest sentinel lymph nodes identified by preoperative lymphoscintigraphy in breast cancer patients.
Improving the quality of decision making in breast cancer: consultation planning template and consultation recording template.
Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity.
MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators?
Racial differences in mammographic breast density.
Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.
Axillary metastasis from a malignant mullerian mixed tumor.
Consultation planning to help breast cancer patients prepare for medical consultations: effect on communication and satisfaction for patients and physicians.
Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.
Improving the accuracy of mammography: volume and outcome relationships.
Magnetic resonance imaging for primary breast cancer management: current role and new applications.
Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers.
New approaches to the imaging, diagnosis, and biopsy of breast lesions.
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma.
Does timely assessment affect the anxiety associated with an abnormal mammogram result?
Ductal lavage for detection of cellular atypia in women at high risk for breast cancer.
MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.
The impact of alternative practices on the cost and quality of mammographic screening in the United States.
Building bridges between physicians and patients: results of a pilot study examining new tools for collaborative decision making in breast cancer.
Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery.
Ductal growth is impeded in mammary glands of C-neu transgenic mice.
Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability.
Integration of breast imaging into cancer management.
MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging.
Biological therapies for breast carcinoma: concepts for improvement in survival.
Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma.
Management of ductal carcinoma in situ.
Prophylactic mastectomy in women with a high risk of breast cancer.
Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging.
Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.
A multicenter randomized trial of DIAC for cyclical mastopathy.
Hormone replacement therapy and breast cancer risk.
Is routine frozen section assessment feasible in the practice environment of the 1990s?
Barriers to care and treatment: the challenge of daily radiation therapy.
Breast.
Should we recommend screening mammography for women aged 40 to 49?
Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast.
Ultrasound tissue characterization of breast biopsy specimens: expanded study.
Cost per anomaly: what does a diaphragmatic hernia cost?
Potentially ineffective care. A new outcome to assess the limits of critical care.
An epitope on the transferrin receptor preferentially exposed during tumor progression in human lymphoma is close to the ligand binding site.
Follicular lymphoma: a model of lymphoid tumor progression in man.
Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.
Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide.
Myocardial performance and extracellular ionized calcium in a severely failing human heart.
A novel method for emergency immobilization of the wrist during cross-country skiing.
